CD274 and cancer: Finally, bsAb continues to be gaining increasing attention for the treatment of TNBC45 and various other cancers,46, 47 with a number of bsAb targeting PD‐L1 and TGF‐β currently in mid‐to‐late clinical trials for multiple cancers.48, 49, 50